Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

BACKGROUND: Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit of new treatments. ESME (Epidemio-Strategy-Medico-Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinda, T., Antoine, A., Jacot, W., Blaye, C., Cottu, P.-H., Diéras, V., Dalenc, F., Gonçalves, A., Debled, M., Patsouris, A., Mouret-Reynier, M.-A., Mailliez, A., Clatot, F., Levy, C., Ferrero, J.-M., Desmoulins, I., Uwer, L., Petit, T., Jouannaud, C., Lacroix-Triki, M., Deluche, E., Robain, M., Courtinard, C., Bachelot, T., Brain, E., Pérol, D., Delaloge, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095121/
https://www.ncbi.nlm.nih.gov/pubmed/33895695
http://dx.doi.org/10.1016/j.esmoop.2021.100114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095121/
https://www.ncbi.nlm.nih.gov/pubmed/33895695
http://dx.doi.org/10.1016/j.esmoop.2021.100114

Ejemplares similares